NCT03018509View on ClinicalTrials.gov

Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

June 20, 2017

Study Completion Date

June 20, 2017

Conditions
Plaque PsoriasisPsoriasisSkin Diseases
Interventions
DRUG

JTE-451

Active drug tablets containing JTE-451

DRUG

Placebo

Placebo tablets identical in appearance to the active drug tablets

Trial Locations (5)

Unknown

Surrey

Markham

Peterborough

Richmond Hill

Waterloo

Sponsors

Lead Sponsor

Akros Pharma Inc.
All Listed Sponsors
lead

Akros Pharma Inc.

INDUSTRY

NCT03018509 - Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects | Biotech Hunter | Biotech Hunter